All In Biotech

Drug Trial Radar · NCT06486558

Relative Bioavailability Study of HU6

A Phase 1, Open-label, Randomized, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jul 24, 2024

Primary completion

Nov 15, 2024

Study completion Dec 15, 2024

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 2-part study. Part 1 will assess the relative bioavailability of the new 450 mg tablet test formulation compared to the 150 mg capsule reference formulation (3 x 150 mg). Part 1 dosing will be conducted in the fasted state. Part 2 will assess the effect of food (and fat content) on the pharmacokinetics of the 450 mg tablet test formulation.

Conditions

  • Healthy

Interventions

  • HU6 450 mg TabletDrug

    new 450 mg tablet test formulation

  • HU6 150 mg Capsules x 3 (Total dose = 450 mg)Drug

    150 mg capsule reference formulation (3 x 150 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve (AUC) from time 0 to last quantifiable time point (AUC0-t),Time frame: 14 days
  2. Maximum concentration (Cmax)Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.